[{"abstract": "The board put off until next week a decision that could force Paul D. Wolfowitz  to resign as president of the bank.", "web_url": "https://www.nytimes.com/2007/04/20/business/20cnd-wolf.html", "snippet": "The board put off until next week a decision that could force Paul D. Wolfowitz  to resign as president of the bank.", "lead_paragraph": "WASHINGTON, April 20 \u2014 The World Bank\u2019s board of directors expressed \u201cgreat concern\u201d today about the mounting furor over the charges of favoritism now dogging the leadership of Paul D. Wolfowitz. But the board put off until next week the rendering of a judgment that could force Mr. Wolfowitz to resign as president of the bank.", "source": "The New York Times", "multimedia": [], "headline": {"main": "World Bank Board to Decide Wolfowitz\u2019s Fate", "kicker": null, "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "organizations", "value": "World Bank", "rank": 1, "major": "N"}, {"name": "persons", "value": "Wolfowitz, Paul D", "rank": 2, "major": "N"}], "pub_date": "2007-04-20T04:00:00+0000", "document_type": "article", "news_desk": "ContinuousNews", "section_name": "Business Day", "byline": {"original": "By Steven R. Weisman", "person": [{"firstname": "Steven", "middlename": "R.", "lastname": "Weisman", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/fa861181-b6f2-5914-972e-e07a10f09fe4", "word_count": 1916, "uri": "nyt://article/fa861181-b6f2-5914-972e-e07a10f09fe4"}, {"abstract": "Diabetes drug developer Metabolex parlayed a strong partnership with Johnson & Johnson and promising early clinical data on its lead compound into a $32 million Series D round of venture capital from crossover investors, which could position the company for a public offering as soon as next year.", "web_url": "https://dealbook.nytimes.com/2007/04/20/metabolex-pumps-vcs-for-32-million/", "snippet": "", "lead_paragraph": "Diabetes drug developer Metabolex parlayed a strong partnership with Johnson & Johnson and promising early clinical data on its lead compound into a $32 million Series D round of venture capital from crossover investors, which could position the company for a public offering as soon as next year.", "source": "The New York Times", "multimedia": [], "headline": {"main": "Metabolex Pumps V.C.s for $32 Million", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [], "pub_date": "2007-04-20T11:14:32+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Dealbook", "person": [{"firstname": "Dealbook", "middlename": null, "lastname": "", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/69b2c84a-6e61-5ad5-aaea-2007219eba2f", "word_count": 86, "uri": "nyt://article/69b2c84a-6e61-5ad5-aaea-2007219eba2f"}]